Back to Directory Edmund Capparelli Email ecapparelli@ucsd.edu Phone 858-246-2750 Institution Univ. of California San Diego Address Univ. of California San Diego 9500 Gilman Drive, MC 0760 La Jolla, CA 92093-0760 Request an Update Affiliated Studies IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure Study Status Pending IMPAACT 2044: Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy DAIDS Number 39132 Research Area Treatment Study Status In Development IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling Show All
IMPAACT 2044: Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy DAIDS Number 39132 Research Area Treatment Study Status In Development
IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling